Sunshine Biopharma (SBFM) vs. Its Rivals Head to Head Review

Sunshine Biopharma (NASDAQ:SBFM) is one of 896 public companies in the “Pharmaceuticals” industry, but how does it compare to its peers? We will compare Sunshine Biopharma to similar businesses based on the strength of its dividends, profitability, risk, earnings, analyst recommendations, institutional ownership and valuation.

Insider and Institutional Ownership

42.0% of Sunshine Biopharma shares are held by institutional investors. Comparatively, 32.6% of shares of all “Pharmaceuticals” companies are held by institutional investors. 0.5% of Sunshine Biopharma shares are held by insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Sunshine Biopharma and its peers top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Sunshine Biopharma	$36.31 million	-$5.97 million	-0.01
Sunshine Biopharma Competitors	$3.55 billion	$3.18 billion	552.64

Sunshine Biopharma’s peers have higher revenue and earnings than Sunshine Biopharma. Sunshine Biopharma is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Sunshine Biopharma and its peers, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sunshine Biopharma	1	1	0	0	1.50
Sunshine Biopharma Competitors	7806	13897	25803	1039	2.41

As a group, “Pharmaceuticals” companies have a potential upside of 25.30%. Given Sunshine Biopharma’s peers stronger consensus rating and higher probable upside, analysts plainly believe Sunshine Biopharma has less favorable growth aspects than its peers.

Profitability

This table compares Sunshine Biopharma and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sunshine Biopharma	-17.94%	-26.36%	-20.60%
Sunshine Biopharma Competitors	-2,380.61%	-219.90%	-15.56%

Volatility & Risk

Sunshine Biopharma has a beta of 1.32, meaning that its stock price is 32% more volatile than the S&P 500. Comparatively, Sunshine Biopharma’s peers have a beta of -3.79, meaning that their average stock price is 479% less volatile than the S&P 500.

Summary

Sunshine Biopharma peers beat Sunshine Biopharma on 9 of the 13 factors compared.

About Sunshine Biopharma

Sunshine Biopharma, Inc. is a biotechnology and pharmaceutical company focused on developing and commercializing therapies for cancer and other medical conditions. Its lead oncology candidate, Adva-27a, is an investigational small-molecule drug designed to inhibit topoisomerase II, an enzyme involved in cancer-cell replication. The company has studied the compound in preclinical models, including models of breast cancer and multidrug-resistant tumors. In addition to its drug-development activities, Sunshine Biopharma has expanded into the pharmaceutical products business through its Canadian operations.